Adverse effects and other aspects of drugs with incretin effect

The most frequent adverse effects related to arGLP-1 are gastrointestinal manifestations, which are usually mild to moderate and diminish after a few days or weeks of continued treatment. Although warnings about the risk of pancreatitis, pancreatic cancer or thyroid cancer continue to be maintained in the data sheets, numerous studies and meta-analyses do not indicate a causal relationship. The relationship with suicidality has not been confirmed either, but they should be prescribed with caution in patients with a history of depression or suicide attempts. The risk of bronchoaspiration should be considered in the perioperative period or with the performance of endoscopic procedures. The effect on body composition is generally favorable, but there is a risk of sarcopenia, which should be prevented. On the other hand, possible benefits are being described for its use in other clinical conditions, such as neurodegenerative diseases or addictions.